Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Core Insights - Calliditas Therapeutics presented additional efficacy analysis of Nefecon (TARPEYO®) and real-world analysis of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN) at ERA 2024 [1][2] Efficacy Analysis - Treatment with Nefecon for 9 months showed a significant estimated glomerular filtration rate (eGFR) benefit compared to continuous treatment with sparsentan [2][4] - The matching-adjusted indirect comparison (MAIC) methodology indicated that Nefecon had favorable effects on eGFR at 9, 12, and 24 months, with mean differences of 5.68 mL/min/1.73 m² (p<0.001), 3.48 mL/min/1.73 m² (p=0.006), and 3.28 mL/min/1.73 m² (p=0.048) respectively [4] Real-World Analysis - The real-world analysis highlighted significant side effects and costs associated with SGC treatment in IgAN patients, including increased incidents of severe infections and healthcare resource utilization [5][6] - The findings emphasized the need for careful consideration of treatment-emergent toxicity before initiating SGC therapy in IgAN patients [5] Company Positioning - Calliditas aims to establish TARPEYO as a cornerstone therapy for IgAN, focusing on treating the underlying autoimmune pathogenesis associated with the disease [3][7] - The company continues to gather evidence supporting the efficacy and safety of TARPEYO in managing IgAN [3]